The estimated impact of the CCR-5 delta32 gene deletion on HIV disease progression varies with study design. Oslo HIV Cohort Study Group - PubMed (original) (raw)
The estimated impact of the CCR-5 delta32 gene deletion on HIV disease progression varies with study design. Oslo HIV Cohort Study Group
A Eskild et al. AIDS. 1998.
Abstract
Objectives: To study the impact of the genotype CCR-5 wild-type +/A32 on the progression rate to AIDS and death, and to discuss sources of bias according to study design.
Methods: A prospective study of 310 HIV-positive subjects with follow-up time from study entry (prevalent cohort), and a prospective study of 105 HIV-positive subjects with well-defined time of HIV seroconversion, with follow-up time from the retrospectively assessed date of HIV seroconversion (retrospective incident cohort).
Results: Slower progression to AIDS among subjects with CCR-5 +/delta32 than those with CCR-5 +/+ genotype was estimated in the prevalent cohort (P=0.07, log-rank test). Slower progression to death from any cause was also estimated for subjects with CCR-5 +/delta32 (P < 0.05, log-rank test). No differences in survival after AIDS diagnosis were seen (P=0.89, log-rank test). No differences in the progression rate to AIDS (P=0.82, log-rank test) or death (P=0.78, log-rank test) were estimated in the retrospective incident cohort.
Conclusions: The varying estimates of the impact of CCR-5 genotype on progression to AIDS in this and other studies, may be real and reflect differences in the dependence of HIV on the CCR-5 receptor, or may be due to systematic errors caused by study design. Several methodological difficulties occur when the factor studied, such as CCR-5 genotype, is associated both with the risk of being HIV-infected and the progression of disease.
Similar articles
- MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.
Bratt G, Leandersson AC, Albert J, Sandström E, Wahren B. Bratt G, et al. AIDS. 1998 May 7;12(7):729-36. doi: 10.1097/00002030-199807000-00009. AIDS. 1998. PMID: 9619804 - Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group.
Meyer L, Magierowska M, Hubert JB, Rouzioux C, Deveau C, Sanson F, Debre P, Delfraissy JF, Theodorou I. Meyer L, et al. AIDS. 1997 Sep;11(11):F73-8. doi: 10.1097/00002030-199711000-00001. AIDS. 1997. PMID: 9302436 - Association between a defective CCR-5 gene and progression to disease in HIV infection.
Balfe P, Churcher Y, Penny M, Easterbrook PJ, Goodall RL, Galpin S, Gotch F, Daniels RS, McKeating JA. Balfe P, et al. AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1229-34. doi: 10.1089/aid.1998.14.1229. AIDS Res Hum Retroviruses. 1998. PMID: 9764905 - The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia.
Pasi KJ, Sabin CA, Jenkins PV, Devereux HL, Ononye C, Lee CA. Pasi KJ, et al. Br J Haematol. 2000 Oct;111(1):136-42. doi: 10.1046/j.1365-2141.2000.02325.x. Br J Haematol. 2000. PMID: 11091193 - Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L. Laurichesse JJ, et al. HIV Med. 2007 May;8(4):213-9. doi: 10.1111/j.1468-1293.2007.00455.x. HIV Med. 2007. PMID: 17461848
Cited by
- Host factors influencing susceptibility to HIV infection and AIDS progression.
Lama J, Planelles V. Lama J, et al. Retrovirology. 2007 Jul 25;4:52. doi: 10.1186/1742-4690-4-52. Retrovirology. 2007. PMID: 17651505 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical